PDCD1 and neoplasm: In advanced melanoma, the anti-PD-1 drug pembrolizumab (formerly MK-3475) showed a high rate of sustained tumor regression with mainly grade 1 or 2 toxic effects in 135 patients, including some with previous disease progression on ipilimumab.